Cargando…
New Developments in the Treatment of Neuroendocrine Tumours – RADIANT-4, NETTER-1 and Telotristat Etiprate
Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has increased significantly in recent years, and whose optimal management remains controversial. We report the latest innovations in their management, in particular the results of three trials concerning the use of...
Autores principales: | Sbardella, Emilia, Grossman, Ashley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Touch Medical Media
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813460/ https://www.ncbi.nlm.nih.gov/pubmed/29632589 http://dx.doi.org/10.17925/EE.2016.12.01.44 |
Ejemplares similares
-
Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours
por: Rico, Karen, et al.
Publicado: (2021) -
Clinical Presentation and Outcomes of Phaeochromocytomas/Paragangliomas in Neurofibromatosis Type 1
por: Al-Sharefi, Ahmed, et al.
Publicado: (2019) -
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
por: Gelhorn, Heather L., et al.
Publicado: (2016) -
Tumour ablation: technical aspects
por: Widmann, Gerlig, et al.
Publicado: (2009) -
Tumour ablation: current role in the kidney, lung and bone
por: Gillams, Alice
Publicado: (2009)